These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings

Elevance Health Inc. (NYSE: ELV ) on Wednesday reported upbeat second-quarter results and raised its full-year guidance.

Adjusted earnings came in at $7.45 per share, beating the analyst consensus estimate of $6.21.

Revenue rose to $49.83 billion, above the consensus estimate of $48.69 billion.

Elevance now expects fiscal 2026 adjusted earnings of at least $27 per share, up from prior guidance of at least $26.75 and above the Wall Street consensus estimate of $26.91.

The company also raised its fiscal 2026 operating cash flow forecast to at least $6 billion.

Elevance Health shares rose 1.8% to $397.20 in pre-market trading.

These analysts made changes to their price targets on Elevance Health following earnings announcement.

Baird analyst Michael Ha maintained the stock with a Neutral and raised the price target from $331 to $393.

Barclays analyst Andrew Mok maintained Elevance Health with an Overweight rating and lowered the price target from $480 to $457.

Guggenheim analyst Jason Cassorla maintained the stock with a Buy and raised the price target from $399 to $455.

Considering buying ELV stock? Here’s what analysts think: Photo via Shutterstock